静脉注射Glu-纤溶酶原减轻胆固醇结晶栓塞诱导的血栓性血管病、急性肾损伤和肾梗死
该研究在小鼠左肾动脉注射胆固醇结晶建立栓塞模型,发现血栓性血管病进行性加重,肾小球滤过率(GFR)于18小时降至最低并出现缺血性坏死;栓塞后4小时静脉注射人血浆Glu-纤溶酶原可剂量依赖性减轻上述病变,1.5 mg/kg完全保护,0.6 mg/kg仅短暂保护,且未见出血并发症。
要点
- 小鼠左肾动脉注射胆固醇结晶后,血栓性血管病进行性加重,GFR于18小时降至最低,12-48小时出现进行性缺血性肾坏死。
- 栓塞后4小时静脉注射人血浆Glu-纤溶酶原可剂量依赖性减轻血栓性血管病、GFR下降和缺血性坏死,未见出血并发症。
- 0.6 mg/kg剂量仅短暂保护微血管闭塞数小时,对18-48小时急性肾损伤或皮质坏死无持续保护;1.5 mg/kg完全保护。
核心结论
- 这些结果首次提供实验证据,表明Glu-纤溶酶原可能是一种创新治疗策略,用于减轻血栓性血管病、急性肾损伤、肾坏死以及胆固醇结晶栓塞综合征的其他临床表现。
研究设计与样本
- 研究为动物实验,向C57BL/6J小鼠左肾动脉注射胆固醇结晶诱导栓塞,主要终点为肾小球滤过率(GFR)。
主要发现
- 胆固醇结晶栓塞后最早2小时起,血栓性血管病在小叶间动脉、弓状动脉和叶间动脉中逐渐进展。
- 血栓性血管病与GFR下降相关,GFR下降在18小时达到峰值,即急性肾损伤,并在注射胆固醇结晶后12-48小时出现进行性缺血性肾坏死。
- 栓塞后4小时静脉注射人血浆Glu-纤溶酶原提取物可剂量依赖性减轻血栓性血管病、GFR下降以及缺血性坏死。
- 注射Glu-纤溶酶原后未发生出血并发症。
- 注射中间剂量(0.6 mg/kg)仅对微血管闭塞产生短暂保护作用,持续数小时,对18-48小时急性肾损伤或皮质坏死无持续保护作用;而1.5 mg/kg具有完全保护作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cholesterol crystal (CC) embolism causes acute kidney injury (AKI) and ischaemic cortical necrosis associated with high mortality. We speculated that sustaining the fibrinolytic system with Glu-plasminogen (Glu-Plg) could be a safe way to attenuate AKI and prevent ischaemic infarction upon CC embolism. METHODS: We induced CC embolism by injecting CC into the left kidney artery of C57BL/6J mice. The primary endpoint was glomerular filtration rate (GFR). RESULTS: Starting as early as 2 h after CC embolism, thrombotic angiopathy progressed gradually in the interlobular, arcuate and interlobar arteries. This was associated with a decrease of GFR reaching a peak at 18 h, i.e. AKI, and progressive ischaemic kidney necrosis developing between 12-48 h after CC injection. Human plasma Glu-Plg extracts injected intravenously 4 h after CC embolism attenuated thrombotic angiopathy, GFR loss as well as ischaemic necrosis in a dose-dependent manner. No bleeding complications occurred after Glu-Plg injection. Injection of an intermediate dose (0.6 mg/kg) had only a transient protective effect on microvascular occlusions lasting for a few hours without a sustained protective effect on AKI at 18-48 h or cortical necrosis, while 1.5 mg/kg were fully protective. Importantly, no bleeding complications occurred. CONCLUSIONS: These results provide the first experimental evidence that Glu-Plg could be an innovative therapeutic strategy to attenuate thrombotic angiopathy, AKI, kidney necrosis and potentially other clinical manifestations of CC embolism syndrome.
引用
- Lyubenov L, Shi C, Zhao D, et al. Intravenous Glu-plasminogen attenuates cholesterol crystal embolism-induced thrombotic angiopathy, acute kidney injury and kidney infarction. Nephrol Dial Transplant. 2023. PMID: 36102665. doi:10.1093/ndt/gfac273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。